Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q1 2025 · 10-Q
Revenue$695.42M$695.42M+5.5% vs Q1 2024 Net Income$12.20M$12.20MN/M vs Q1 2024 EPS Diluted$0.04$0.04N/M vs Q1 2024 Gross Profit$255,891,000+7.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flow$7,408,000N/M Free Cash Flowderived-$5,754,000N/M Margins · derivedGross margin36.8%+0.7 pt vs Q1 2024
Operating margin14.4%+16.1 pt vs Q1 2024
Net margin1.8%+15.7 pt vs Q1 2024
ended Mar 31, 2025 · filed May 7, 2025 · 37 d after period end